About

Xycota Biosciences is an advanced biotechnology company dedicated to the physical restoration of the human brain. While traditional Central Nervous System (CNS) therapies focus primarily on symptom management and neurotransmitter modulation, Xycota is pioneering the next era of neuro-restoration: targeted synaptogenesis.

Our core mission is to decouple the therapeutic healing properties of psilocin from its hallucinogenic effects. Building upon peer-reviewed preclinical findings, we recognize that the true restorative benefits of psilocin are driven by the BDNF/TrkB signaling pathway—the brain's intrinsic repair circuitry.

To translate this mechanism into a clinical reality, Xycota utilizes a proprietary fungal exosome delivery system designed to safely transit the blood-brain barrier (BBB) and deliver precision-loaded therapies. By bypassing the 5-HT2A "trip" receptors and directly upregulating BDNF, our platform promotes the regrowth of damaged neural connections without psychedelic intensity.

Our clinical pipeline is strategically designed for rapid validation and commercialization, targeting high-unmet-need indications with clear regulatory pathways. Our lead program targets Frontotemporal Dementia (FTD) via an Orphan Drug Designation (ODD) strategy, providing a capital-efficient wedge to establish human proof-of-concept. Expansion indications include post-concussion cognitive restoration (mTBI) and broader neurodegenerative conditions, such as early-stage Alzheimer's.

Xycota is anchored by a world-class scientific and corporate leadership team. President and Co-Founder Brad Listermann brings decades of technology commercialization, IP development, and capital market strategy. He is joined by Founder and CSO Dr. Marvin S. Hausman, MD, a renowned immunologist with over 50 years of CNS drug development experience. Dr. Hausman’s track record includes co-founding Medco Research (acquired by Pfizer), architecting six successful NDAs, and securing foundational orphan drug designations in the U.S. and EU.

By merging precision exosome delivery, a validated biological pathway, and elite institutional execution, Xycota Biosciences is engineered to move medicine beyond symptom management and into the structural repair of the mind.